RXi wins new patents
RXi Pharmaceuticals Corp. of Marlborough said it has received a new patent on a delivery system for the treatment diseases with an inflammatory component.
RXi said the system delivers its patented RNAi compounds, known as rxRNAori, to certain cells for the treatment of diseases like macular degeneration, rheumatoid arthritis, and Crohn’s disease.
The patent “broadens the breadth of RXi’s … delivery platform for the targeted delivery of RNAi therapeutics to specific cells,” according to a statement. The patent expires in 2029.
Meanwhile, the European Union has also granted RXi a patent for its siRNA sequence targeting several eye diseases, such as allergic conjunctivitis, limbic injury, and retinitis. That patent will expire in 2024.
“Not only do these patents deepen our ability to broadly protect our proprietary and novel technology platform, it also reinforces the potential for future commercial and business development opportunities,” RXi CEO Geert Cauwenbergh said in a statement.
WBJ Web Partners
Most Recent
Most Recent
0 Comments